openPR Logo
Press release

Follicular Lymphoma Treatment Market - Global Industry Insights, and Opportunity Analysis, 2025

10-23-2017 03:42 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Follicular Lymphoma Treatment Market - Global Industry

Lymphoma refers to the cancer of lymphatic system, which affects the cells of the immune system known as lymphocytes resulting into abnormal multiplication and growth of the cells. Lymphocytes are the white blood cells that protects the body from the infection. It is of two types, namely, Non-Hodgkin and Hodgkin lymphoma. Follicular lymphoma is a type of Non-Hodgkin Lymphoma that affects the lymphocytes. It is the most common indolent type of Non- Hodgkin lymphoma. Follicular lymphoma has symptoms such as enlargement of the lymph nodes in the neck, groin, and abdomen, shortness of breath, weight loss, night sweats, and fatigue.

Follicular lymphoma can be treated on the basis of the acuteness of associated symptoms and on cancer growth rate. Radiation and chemotherapy are presently the responsive treatment for follicular lymphoma. However, radiation alone can be used for the treatment of follicular lymphoma in most of the cases. In more advanced cases chemotherapy or a monoclonal antibody rituximab, alone or the combination of both are used for the treatment of follicular lymphoma. Moreover, monoclonal antibodies are more predominant over the chemotherapy, as they act directly by targeting on tumor cells and thereby, increases immune cells that destructs tumor, which increases response to the treatment.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/907

Rituximab a monoclonal antibody used as a therapeutic agent is expected to augment the market growth

The major factors contributing to the growth of global follicular lymphoma treatment market are rising adoption of monoclonal antibodies for targeted therapies. According to the National Center for Biotechnology Information (NCBI), in 2016, monoclonal antibodies are considered as the successful therapeutics in the cancer treatment. The use of monoclonal antibodies is expected to overcome the side effects, which are generally exhibited by traditional therapies such as radiation and chemotherapy. Therefore, the monoclonal antibody such as rituximab, an anti-CD20 antibody can act as a potential therapeutic agent for the treatment of follicular lymphoma cancer. Moreover, increase in the number of incidence of relapsed follicular lymphoma is also expected to drive the market growth as the number of relapse for the disease results in the same patient availing the treatment multiple times. However, the factors hindering the growth of follicular lymphoma treatment market are the availability of the drugs and high cost of the treatment.

Follicular Lymphoma Treatment Market Taxonomy

Follicular lymphoma treatment is segmented on the basis of treatment type, end user, and geography

On the basis of treatment type, the global follicular lymphoma treatment market is segmented into

Radiation
Targeted therapy
Chemotherapy
Monoclonal antibody
Stem cell transplant

On the basis of end user, the global follicular lymphoma treatment market is segmented into

Hospitals
Speciality centers
Clinics
Cancer Research Institutes

Rising prevalence of follicular lymphoma cases is expected to fuel the market growth in North America

On the basis of geography, the global follicular lymphoma treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global follicular lymphoma treatment market, owing to the rise in the follicular lymphoma cases. According to the American Cancer Society (ACS), in 2017, around 72,240 people including adults and children are expected to get diagnosed with follicular lymphoma. Moreover, a series of studies are initiated in the National Cancer Institute, in U.S., to assess the novel emerging sequencing technologies in cancer, as part of the cancer genome characterization. Furthermore, Asia Pacific is expected to hold a major market share in the global follicular lymphoma treatment market over the forecast period. This is mainly owing to advanced research practices adopted by the government and private research institutes of China to curb the follicular lymphoma cancer.

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/follicular-lymphoma-treatment-market-907

The innovative Drug Aliqopa launched by Bayer AG’s is expected to propel the market growth

Some of the key players operating in the global follicular lymphoma treatment market include Roche, Spectrum Pharmaceuticals, Johnson and Johnson, CTI Biopharma, Celgene, AbbVie Inc., Novartis, Amgen, Merck & Co. (MRK), Seattle Genetics, Pharmacyclics/ Bristol-Myers Squibb (BMY), and Bayer AG’S. In 2017, Bayer AG’s has launched an innovative drug, Aliqopa, also known as copanlisib, which is a kinase inhibitor that block certain enzymes responsible in promoting cell growth.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Follicular Lymphoma Treatment Market - Global Industry Insights, and Opportunity Analysis, 2025 here

News-ID: 781921 • Views:

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic foot ulcers treatment market
Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017 – 2025
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2025 globally
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for Follicular

Follicular Lymphoma Treatment Market Entry Strategies, Countermeasures of Econom …
The exclusive research report on 'Follicular Lymphoma Treatment Market' now available with 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, offers a detailed analysis of the factors influencing the global business sphere. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Follicular Lymphoma Treatment Market. The research report incorporates a
Follicular Unit Extraction (FUE) Systems Market 2021 | Detailed Report
ReportsnReports publishes the report titled Follicular Unit Extraction (FUE) Systems that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital
Follicular Lymphoma Drugs Market 2021 | Detailed Report
Follicular Lymphoma Drugs Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Follicular Lymphoma Drugs Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4460211 The report provides a comprehensive analysis of company profiles listed below: - Genentech (Roche) - Bristol-Myers Squibb -
Hair Transplant Market by Surgery Type (Follicular Unit Strip Surgery, Follicula …
The Global Hair Transplant Market provides industry overview in terms of revenue (in US$ Mn). Furthermore, the report includes drivers, restraints, trends and opportunity of the Hair transplant market and their impact on each country during the forecast period. Hair Transplantation is a surgical technique used to treat alopecia or baldness. Hair transplantation market report is segmented as surgical and non- surgical technique. The Surgical techniques include Robotic hair transplantation, follicular
Follicular Lymphoma Treatment Market: Industry Size, Share, Growth, Forecasts 20 …
MarketResearchReports.Biz announces addition of new report "Follicular Lymphoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its database. The objectives of this study are as follows: To define, describe, and forecast the "Follicular Lymphoma Treatment" market by type, application, component, delivery model, end user, and region To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges) To analyze micromarkets with
A Comprehensive Study exploring Follicular Lymphoma Treatment Market
HTF MI recently introduced Global Follicular Lymphoma Treatment Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. At present, the market is developing its presence and some of the key players from the complete study are Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Inc., Celltrion, Inc., Cellular Biomedicine Group, Inc., Coherus BioSciences, Inc., CTI BioPharma Corp.,